TENSIVE 

CONTROLS, INC

Reach us at
(573) 881-5080

The basis for this technological advance was the recognition of an overlapping RFamide-like pharmacophore within the melanocortin pharmacophore (HFRW) that mediated cardiovascular activity.  The development of a synthetic approach to suppress RFamide activity formed the basis for the patent.  Continued advancements led to the discovery (patent-pending) of a platform technology for producing drug-like peptides with multiple applications.

IP PORTFOLIO


Issued-USPTO  #8,541,545

Stabilized Melanocortin Ligands

08/30/2010

Granted-EU  #10 812 701.0

Stabilized Melanocortin Ligands

08/30/2010

Pending-USPTO  #14/384,694

Melanocortin Analogs Having Enhanced Activity and Transport

3/20/2012

Pending-EU  #13760918.6

Melanocortin Analogs Having Enhanced Activity and Transport

3/20/2012

Provisional-PCT;  #1020847; Anti-Microbial Peptides

9/19/2015;


Provisional-USPTO  #008077-0907964

Angiotensin(1-7) Analogs & Methods Relating Thereto

9/17/2015

The advantage of Tensive’s approach over other attempts to develop melanocortins as drugs is that our analogs are free of adverse cardiovascular side effects, and are more drug-like (more stable in plasma, orally active, predictable PK).  Previous attempts to develop melanocortin-based drugs failed due to cardioascular side-effects in both experimental studies and clinical trials. A U.S. patent for the suppression of cardiovascular  side-effects in melanocortin-based therapeutics has issued and related patents are pending.  

Tensive Controls Cancer Cachexia Peptide platform